BioPharma Resources

Drug Trial Radar · NCT07634471

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

960

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Jul 23, 2032

Study completion Jul 23, 2035

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)

Conditions

  • Follicular Lymphoma

Interventions

  • MK-1045Biological

    Intravenous (IV) infusion

  • RituximabBiological

    IV infusion

  • Rituximab biosimilarBiological

    IV infusion

  • BendamustineDrug

    IV infusion

  • CyclophosphamideDrug

    IV infusion

  • VincristineDrug

    IV infusion

  • PrednisoneDrug

    Per approved product label

  • PrednisoloneDrug

    Per approved product label

  • Doxorubicin HydrochlorideDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 15 months
  2. Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 12 months
  3. Part 1: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 36 days
  4. Part 1: Complete Response (CR) RateTime frame: Up to approximately 60 months
  5. Part 2: Progression-Free Survival (PFS)Time frame: Up to approximately 63 months

Locations

40 sites in 14 countries. Site status is shown where the registry gives one.

  • City of Hope - Duarte Cancer Center ( Site 1301)

    Duarte, California · Recruiting

  • University of Kentucky ( Site 1303)

    Lexington, Kentucky · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1311)

    Hackensack, New Jersey · Recruiting

  • Icahn School of Medicine at Mount Sinai ( Site 1325)

    New York, New York · Recruiting

  • Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)

    Durham, North Carolina · Recruiting

  • University Hospitals of Cleveland ( Site 1321)

    Cleveland, Ohio · Recruiting

  • SCRI Oncology Partners ( Site 7000)

    Nashville, Tennessee · Recruiting

  • University of Texas-MD Anderson Cancer Center ( Site 1323)

    Houston, Texas · Recruiting

  • Hospital Privado Universitario de Córdoba ( Site 0102)

    Córdoba, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0105)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Aleman ( Site 0101)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Sanatorio Nuestra Senora del Rosario ( Site 0104)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Concord Repatriation General Hospital ( Site 0202)

    Concord, New South Wales, Australia · Recruiting

  • Box Hill Hospital ( Site 0201)

    Box Hill, Victoria, Australia · Recruiting

  • Biocenter ( Site 0402)

    Concepción, Biobio, Chile · Recruiting

  • Fundacion Arturo Lopez Perez FALP ( Site 0404)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0407)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer hospital ( Site 0501)

    Beijing, Beijing Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center ( Site 0504)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau ( Site 0604)

    Tours, Indre-et-Loire, France · Recruiting

  • Evangelismos General Hospital of Athens ( Site 1501)

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens "Laiko" ( Site 1502)

    Athens, Attica, Greece · Recruiting

  • Hadassah Medical Center ( Site 0701)

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center ( Site 0702)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center ( Site 0704)

    Tel Aviv, Israel · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1601)

    Rome, Lazio, Italy · Recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo ( Site 1602)

    Candiolo, Torino, Italy · Recruiting

  • Pratia MCM Krakow ( Site 1702)

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1701)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Samsung Medical Center ( Site 0801)

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall de Hebron ( Site 0903)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Gregorio Maranon ( Site 0902)

    Madrid, Spain · Recruiting

  • Hospital Universitario de Salamanca ( Site 0906)

    Salamanca, Spain · Recruiting

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)

    Badalona, Barcelona, Spain · Recruiting

  • Hospital Virgen de la Victoria ( Site 0905)

    Málaga, Malaga, Spain · Recruiting

  • National Taiwan University Hospital ( Site 1001)

    Taipei, Taiwan · Recruiting

  • Chang Gung Medical Foundation-Linkou Branch ( Site 1002)

    Taoyuan, Taiwan · Recruiting

  • Hacettepe Universite Hastaneleri ( Site 1110)

    Ankara, Turkey (Türkiye) · Recruiting

  • Sisli Florence Nightingale Hastanesi ( Site 1112)

    Istanbul, Turkey (Türkiye) · Recruiting

  • Ondokuz Mayıs Universitesi ( Site 1113)

    Samsun, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.